Advocacy briefs on investment in TB vaccine R&D

Back to the "HIV and Co-Infections News" list

Investment toolbox to advance TB vaccine development through joint action

The G20 includes many countries with a high burden of TB and is uniquely positioned to lead TB vaccine development and delivery through joint, sustained, and scaled-up investments. A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development. At least one new TB vaccine must be licensed and approved by 2025 to meet the World Health Organization’s goal of ending TB by 2030.


Member States must commit to invest in TB vaccine R&D

The TB Vaccine Advocacy Roadmap (TB Vax ARM) developed a one-pager on why Member States must commit to invest in TB vaccine research and development (R&D). It provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research to reach the annual $1.25 billion funding target and develop and roll-out new TB vaccines within the next five years, no later than 2028.


For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#23, 20 July 2023) with the latest TB advocacy and research updates.


Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.